Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection

Vascular Pharmacology

Volumn 51, Issue 4, 2009, Pages 253-261

  Nadaud, Sophie ^a,b   Dupuis, Morgan ^a,b   Brocheriou, Isabelle ^a,b,c   Haloui, Mounsif ^b,d   Louedec, Liliane ^b,d   Capron, Frédérique ^c   Michel, Jean Baptiste ^b,d   Soubrier, Florent ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Microarray; PPARalpha; Smad6; Smad7; Statin; Transforming Growth Factor beta

Indexed keywords

ATORVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTERIAL WALL THICKENING; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HYPERTENSION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER; TREATMENT RESPONSE;

ANIMALS; AORTA; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HYPERTENSION; MALE; NG-NITROARGININE METHYL ESTER; PYRROLES; RATS; RATS, INBRED F344;

EID: 70349970274     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.06.011     Document Type: Article

References (55)

1. Arnal J.F., Warin L., and Michel J.B. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J. Clin. Invest. 90 (1992) 647-652
2. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., and Eppig J.T. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25 (2000) 25-29
3. Bustos C., Hernandez-Presa M.A., Ortego M., Tunon J., Ortega L., Perez F., Diaz C., Hernandez G., and Egido J. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 32 (1998) 2057-2064
4. Chen Y., Ohmori K., Mizukawa M., Yoshida J., Zeng Y., Zhang L., Shinomiya K., Kosaka H., and Kohno M. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ. J. 71 (2007) 144-152
5. Corseaux D., Ollivier V., Fontaine V., Huisse M.G., Philippe M., Louedec L., Vranckx R., Ravanat C., Lanza F., and Angles-Cano E. Hemostasis imbalance in experimental hypertension. Mol. Med. 8 (2002) 169-178
6. Dayoub H., Achan V., Adimoolam S., Jacobi J., Stuehlinger M.C., Wang B.Y., Tsao P.S., Kimoto M., Vallance P., Patterson A.J., and Cooke J.P. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108 (2003) 3042-3047
7. Delbosc S., Haloui M., Louedec L., Dupuis M., Cubizolles M., Podust V.N., Fung E.T., Michel J.B., and Meilhac O. Proteomic analysis permits the identification of new biomarkers of arterial wall remodeling in hypertension. Mol. Med. 14 (2008) 383-394
8. Douillet C.D., Velarde V., Christopher J.T., Mayfield R.K., Trojanowska M.E., and Jaffa A.A. Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-beta and MAPK. Am. J. Physiol. Heart Circ. Physiol. 279 (2000) H2829-2837
9. Dupuis M., Soubrier F., Brocheriou I., Raoux S., Haloui M., Louedec L., Michel J.B., and Nadaud S. Profiling of aortic smooth muscle cell gene expression in response to chronic inhibition of nitric oxide synthase in rats. Circulation 110 (2004) 867-873
10. Egan E.A., and Solomon M.J. Cyclin-stimulated binding of Cks proteins to cyclin-dependent kinases. Mol. Cell. Biol. 18 (1998) 3659-3667
11. Fischer J.W., Steitz S.A., Johnson P.Y., Burke A., Kolodgie F., Virmani R., Giachelli C., and Wight T.N. Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2391-2396
12. Giachelli C.M., Bae N., Almeida M., Denhardt D.T., Alpers C.E., and Schwartz S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest. 92 (1993) 1686-1696
13. Giachelli C.M., Speer M.Y., Li X., Rajachar R.M., and Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ. Res. 96 (2005) 717-722
14. Gonzalez W., Fontaine V., Pueyo M.E., Laquay N., Messika-Zeitoun D., Philippe M., Arnal J.F., Jacob M.P., and Michel J.B. Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals. Hypertension 36 (2000) 103-109
15. Haloui M., Meilhac O., Jandrot-Perrus M., and Michel J.B. Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin. Eur. J. Pharmacol. 474 (2003) 175-184
16. Henck J.W., Craft W.R., Black A., Colgin J., and Anderson J.A. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Toxicol. Sci. 41 (1998) 88-99
17. Henrion D., Dechaux E., Dowell F.J., Maclour J., Samuel J.L., Levy B.I., and Michel J.B. Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2. Br. J. Pharmacol. 121 (1997) 83-90
18. Hernandez-Presa M.A., Martin-Ventura J.L., Ortego M., Gomez-Hernandez A., Tunon J., Hernandez-Vargas P., Blanco-Colio L.M., Mas S., Aparicio C., and Ortega L. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 160 (2002) 49-58
19. Heximer S.P., Knutsen R.H., Sun X., Kaltenbronn K.M., Rhee M.H., Peng N., Oliveira-dos-Santos A., Penninger J.M., Muslin A.J., and Steinberg T.H. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J. Clin. Invest. 111 (2003) 445-452
20. Iozzo R.V. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J. Biol. Chem. 274 (1999) 18843-18846
21. Isoda K., Nishikawa K., Kamezawa Y., Yoshida M., Kusuhara M., Moroi M., Tada N., and Ohsuzu F. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ. Res. 91 (2002) 77-82
22. Kaneyuki U., Ueda S., Yamagishi S., Kato S., Fujimura T., Shibata R., Hayashida A., Yoshimura J., Kojiro M., Oshima K., and Okuda S. Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascul. Pharmacol. 46 (2007) 286-292
23. Koyanagi M., Egashira K., Kubo-Inoue M., Usui M., Kitamoto S., Tomita H., Shimokawa H., and Takeshita A. Role of transforming growth factor-beta1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. Hypertension 35 (2000) 86-90
24. Landrier J.F., Thomas C., Grober J., Duez H., Percevault F., Souidi M., Linard C., Staels B., and Besnard P. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J. Biol. Chem. 279 (2004) 45512-45518
25. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
26. Ledingham J.M., and Laverty R. Fluvastatin remodels resistance arteries in genetically hypertensive rats, even in the absence of any effect on blood pressure. Clin. Exp. Pharmacol. Physiol. 29 (2002) 931-934
27. Li C., and Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 31-36
28. Li G., Oparil S., Sanders J.M., Zhang L., Dai M., Chen L.B., Conway S.J., McNamara C.A., and Sarembock I.J. Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro. Atherosclerosis 188 (2006) 292-300
29. Liaw L., Almeida M., Hart C.E., Schwartz S.M., and Giachelli C.M. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res. 74 (1994) 214-224
30. Luvara G., Pueyo M.E., Philippe M., Mandet C., Savoie F., Henrion D., and Michel J.B. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1408-1416
31. McGillicuddy F.C., O'Toole D., Hickey J.A., Gallagher W.M., Dawson K.A., and Keenan A.K. TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vasc. Pharmacol. 44 (2006) 469-475
32. Michel J.B., Xu Y., Blot S., Philippe M., and Chatellier G. Improved survival in rats administered NG-nitro L-arginine methyl ester due to converting enzyme inhibition. J. Cardiovasc. Pharmacol. 28 (1996) 142-148
33. Ni W., Egashira K., Kataoka C., Kitamoto S., Koyanagi M., Inoue S., and Takeshita A. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ. Res. 89 (2001) 415-421
34. Paumelle R., Blanquart C., Briand O., Barbier O., Duhem C., Woerly G., Percevault F., Fruchart J.C., Dombrowicz D., Glineur C., and Staels B. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ. Res. 98 (2006) 361-369
35. Perez-Guerrero C., Alvarez de Sotomayor M., Jimenez L., Herrera M.D., and Marhuenda E. Effects of simvastatin on endothelial function after chronic inhibition of nitric oxide synthase by L-NAME. J. Cardiovasc. Pharmacol. 42 (2003) 204-210
36. Rehn A.P., Chalk A.M., and Wendel M. Differential regulation of osteoadherin (OSAD) by TGF-beta1 and BMP-2. Biochem. Biophys. Res. Commun. 349 (2006) 1057-1064
37. Schultz-Cherry S., Ribeiro S., Gentry L., and Murphy-Ullrich J.E. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J. Biol. Chem. 269 (1994) 26775-26782
38. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., and Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama 285 (2001) 1711-1718
39. Seko T., Ito M., Kureishi Y., Okamoto R., Moriki N., Onishi K., Isaka N., Hartshorne D.J., and Nakano T. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ. Res. 92 (2003) 411-418
40. Shanahan C.M., Proudfoot D., Tyson K.L., Cary N.R., Edmonds M., and Weissberg P.L. Expression of mineralisation-regulating proteins in association with human vascular calcification. Z. Kardiol. 89 Suppl 2 (2000) 63-68
41. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1712-1719
42. Tang K.M., Wang G.R., Lu P., Karas R.H., Aronovitz M., Heximer S.P., Kaltenbronn K.M., Blumer K.J., Siderovski D.P., Zhu Y., and Mendelsohn M.E. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat. Med. 9 (2003) 1506-1512
43. Teramoto H., Malek R.L., Behbahani B., Castellone M.D., Lee N.H., and Gutkind J.S. Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes. Oncogene 22 (2003) 2689-2697
44. Tomita H., Egashira K., Ohara Y., Takemoto M., Koyanagi M., Katoh M., Yamamoto H., Tamaki K., Shimokawa H., and Takeshita A. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32 (1998) 273-279
45. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U S A. 98 (2001) 5116-5121
46. Vaughan C.J., Murphy M.B., and Buckley B.M. Statins do more than just lower cholesterol. Lancet 348 (1996) 1079-1082
47. Vieira Jr. J.M., Rodrigues L.T., Mantovani E., Delle H., Mattar A.L., Malheiros D.M., Noronha I.L., Fujihara C.K., and Zatz R. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease. Nephron. Physiol. 101 (2005) 82-91
48. Wassmann S., Laufs U., Baumer A.T., Muller K., Ahlbory K., Linz W., Itter G., Rosen R., Bohm M., and Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37 (2001) 1450-1457
49. Wassmann S., Laufs U., Muller K., Konkol C., Ahlbory K., Baumer A.T., Linz W., Bohm M., and Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 300-305
50. Wendel M., Sommarin Y., and Heinegard D. Bone matrix proteins: isolation and characterization of a novel cell-binding keratan sulfate proteoglycan (osteoadherin) from bovine bone. J. Cell Biol. 141 (1998) 839-847
51. Wolfrum S., Jensen K.S., and Liao J.K. Endothelium-dependent effects of statins. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 729-736
52. Wong A.P., Nili N., and Strauss B.H. In vitro differences between venous and arterial-derived smooth muscle cells: potential modulatory role of decorin. Cardiovasc. Res. 65 (2005) 702-710
53. Yagi S., Aihara K., Ikeda Y., Sumitomo Y., Yoshida S., Ise T., Iwase T., Ishikawa K., Azuma H., Akaike M., and Matsumoto T. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ. Res. 102 (2008) 68-76
54. Yano M., Matsumura T., Senokuchi T., Ishii N., Murata Y., Taketa K., Motoshima H., Taguchi T., Sonoda K., and Kukidome D. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ. Res. 100 (2007) 1442-1451
55. Young W., Mahboubi K., Haider A., Li I., and Ferreri N.R. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ. Res. 86 (2000) 906-914